<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108274</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-010</org_study_id>
    <secondary_id>U1111-1193-2774</secondary_id>
    <nct_id>NCT03108274</nct_id>
  </id_info>
  <brief_title>A Phase I DDI Study Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil</brief_title>
  <official_title>A Three-Part Phase I Study to Determine the Potential Drug Interaction Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the potential drug interaction between ACH-0144471
      and Midazolam, Fexofenadine and Mycophenolate Mofetil
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 3-part study with each part being an open-label, fixed sequence, 2-treatment
      study in healthy adult subjects. Part 1, Part 2 and Part 3 may be conducted concurrently or
      separately and the order of the parts may be determined accordingly to the needs of the
      ACH-0144471 development program. A total of 12 subjects will participate in each study part.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Actual">June 16, 2017</completion_date>
  <primary_completion_date type="Actual">June 2, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This will be a 3-part study with each part being an open-label, fixed sequence, 2-treatment study in healthy adult subjects. Part 1, Part 2 and Part 3 may be conducted concurrently or separately and the order of the parts may be determined according to the needs of the ACH-0144471 development program</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Interaction Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil</measure>
    <time_frame>Up to 26 Days</time_frame>
    <description>To determine the effect of multiple oral doses of ACH-0144471 on the pharmacokinetics (PK) of midazolam, fexofenadine and mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG) as measured by maximum observed concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Interaction Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil</measure>
    <time_frame>Up to 26 Days</time_frame>
    <description>To determine the effect of multiple oral doses of ACH-0144471 on the pharmacokinetics (PK) of midazolam, fexofenadine and mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG) as measured by area under the curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Interaction Between ACH-0144471 and Midazolam</measure>
    <time_frame>Up to 26 Days</time_frame>
    <description>To assess the safety and tolerability of multiple oral doses of ACH-0144471 with midazolam measured by adverse events (AE's), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Interaction Between ACH-0144471 and Fexofenadine</measure>
    <time_frame>Up to 26 Days</time_frame>
    <description>To assess the safety and tolerability of multiple oral doses of ACH-0144471 with fexofenadine measured by adverse events (AE's), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Interaction Between ACH-0144471 and Mycophenolate Mofetil</measure>
    <time_frame>Up to 26 Days</time_frame>
    <description>To assess the safety and tolerability of multiple oral doses of ACH-0144471 with mycophenolate mofetil measured by adverse events (AE's), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Drug Interaction Potentiation</condition>
  <arm_group>
    <arm_group_label>Part 1, Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of Midazolam Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of ACH-0144471 Day 1-4 Single oral single dose of Midazolam on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Fexofenadine on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of ACH-0144471 on Days 1-6 Single dose of Fexofenadine on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3, Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Mycophenolate Mofetil on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3, Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of ACH-0144471 on Days 1-6 Single dose of Mycophenolate Mofetil on Day 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1, Period 1</intervention_name>
    <description>Midazolam single oral dose</description>
    <arm_group_label>Part 1, Period 1</arm_group_label>
    <other_name>Midazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1, Period 2</intervention_name>
    <description>Multiple doses ACH-0144471 Single dose Midazolam</description>
    <arm_group_label>Part 1, Period 2</arm_group_label>
    <other_name>ACH-0144471</other_name>
    <other_name>Midazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2, Period 1</intervention_name>
    <description>Fexofenadine single oral dose</description>
    <arm_group_label>Part 2, Period 1</arm_group_label>
    <other_name>Fexofenadine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2, Period 2</intervention_name>
    <description>Multiple doses ACH-0144471 Single dose Fexofenadine</description>
    <arm_group_label>Part 2, Period 2</arm_group_label>
    <other_name>ACH-0144471</other_name>
    <other_name>Fexofenadine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 3, Period 1</intervention_name>
    <description>Mycophenolate Mofetil single oral dose</description>
    <arm_group_label>Part 3, Period 1</arm_group_label>
    <other_name>Mycophenolate Mofetil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 3, Period 2</intervention_name>
    <description>Multiple doses ACH-0144471 Single dose Mycophenolate Mofetil</description>
    <arm_group_label>Part 3, Period 2</arm_group_label>
    <other_name>ACH-0144471</other_name>
    <other_name>Mycophenolate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects age 18-60

          -  Have a BMI of 18.5 to 32 kg/m2 with a minimum body weight of 50kg

          -  Females must be of non-childbearing potential

          -  Males must agree to use effective contraception during and for 90 days after last dose
             of study drug

          -  Willing to answer inclusion and exclusion criteria

          -  Give voluntary consent

          -  Willing to comply with visit schedule and all procedures and tests

        Exclusion Criteria:

          -  Mentally or legally incapacitated or significant emotional problems

          -  History of disease

          -  Any condition which might interfere with drug absorption

          -  Positive test for HIV, Hepatitis B and/or C

          -  History of sensitivity to study medication, or other drug allergy

          -  Body temperature greater than 38 Celsius

          -  History of febrile illness within 14 days of first dose

          -  History of meningococcal infection

          -  Positive urine drug test

          -  Current tobacco users and smokers

          -  Consumption of alcohol within 72 hours of study drug administration

          -  Participated in another clinical study within 28 days prior to first dose

          -  Previous participation in an ACH-0144471 study

          -  12-lead ECG with significant findings

          -  Significant laboratory abnormalities

          -  Use of prescription medications within 14 days of first dose

          -  Use of medications known to induce hepatic microsomal enzyme cytochrome

          -  Prior history or current evidence of biliary cholestasis

          -  Blood donation of more than 500mL within 3 months of first dose

          -  Received a blood transfusion or blood products within 6 months to first dose

          -  Unwilling or unable to comply with study protocol

          -  Males subjects with female partner who is pregnant, nursing or planning to become
             pregnant within 90 days of last study dose

          -  Received live attenuated vaccine within 30 days or other vaccine within 14 days of
             first dose

          -  Have or history of Gilberts syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Hamilton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland Clinical Studies Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1150</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Midazolam</keyword>
  <keyword>Fexofenadine</keyword>
  <keyword>Mycophenolate Mofetil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

